Navigation Links
ViroPharma to Discuss Commercialization and Launch of Cinryze(TM) on November 5, 2008
Date:10/30/2008

- Conference Call to Be Held at 4:00 P.M. Eastern Time -

EXTON, Pa., Oct. 30 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) will host a conference call and live audio webcast at 4:00 p.m. Eastern Time on Wednesday, November 5, 2008 to discuss the commercialization plans and launch of Cinryze C1 Inhibitor (human), which has been recently approved by the U.S. Food and Drug Administration for routine prophylaxis against angioedema attacks in adolescent and adult patients with HAE.

The live webcast of the conference call will be accessible via ViroPharma's corporate website at http://www.viropharma.com. An audio archive will be available at the same address until November 20, 2008. To participate in the conference call, please dial (877) 366-0713 (domestic) and (302) 607-2000 (international). After placing the call, please tell the operator you wish to join the ViroPharma investor conference call.

About ViroPharma Incorporated

ViroPharma Incorporated is a biopharmaceutical company dedicated to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma commercializes Vancocin(R) (vancomycin hydrochloride capsules, USP), approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains, and Cinryze(TM) (C1 inhibitor (human)) for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), also known as C1 inhibitor deficiency (for prescribing information on ViroPharma's commercial products, please download the package inserts at http://www.viropharma.com/Products.aspx). ViroPharma currently focuses its drug development activities in diseases including cytomegalovirus (CMV), HAE and C. difficile.

ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's web site, http://www.viropharma.com. The company encourages investors to consult these sections for more information on ViroPharma and our business.


'/>"/>
SOURCE ViroPharma Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. ViroPharma Incorporated Reports Third Quarter 2008 Financial Results
2. ViroPharma to Release 2008 Second Quarter Financial Results on July 30, 2008
3. ViroPharma Incorporated Reports First Quarter 2008 Financial Results
4. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2007 Financial Results
5. Vincent J. Milano to Succeed Michel de Rosen as President and Chief Executive Officer of ViroPharma
6. ViroPharma Provides Update on Vancocin(R)
7. ViroPharma Augments Senior Management
8. ViroPharma to Present at the 26th Annual JP Morgan Healthcare Conference
9. ViroPharma Receives European Orphan Drug Designation for CAMVIA(TM)
10. ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results
11. ViroPharma to Present at the UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... ... ... “The Trials I Face to Receive God’s Grace”: a mesmerizing take ... goals to better one’s life through God. “The Trials I Face to Receive God’s ... wrong places, found a love for writing. Green feels that expressing his feelings through ...
(Date:9/20/2017)... ... ... Houston, Texas, investment firm CORDA Investment Management, LLC, believes in giving back. ... work and rolled up their sleeves to help with relief efforts. The team picked ... process of rebuilding. , CORDA founder Bonner C. Barnes notes that investment management firms ...
(Date:9/20/2017)... ... September 20, 2017 , ... “The Foggy Road to Moorwick”: the adventures of a young ... creation of published author, Jeanine Liston, a busy mother of five who used her time ... been writing this book for over twenty years. It was a way to give ...
(Date:9/20/2017)... (PRWEB) , ... September 20, 2017 , ... “Monique”: ... into uncomfortable situations. “Monique” is the creation of published author, Colleen Crispi, has owned ... Since then Crispi has been involved in real estate and cooking. , “The ...
(Date:9/19/2017)... ... September 19, 2017 , ... DeSola Group, ... marketing leader, Denise Flannery, to its strategic advisory and client development team. ... will work with clients across different industries to develop and implement market-justified strategies, ...
Breaking Medicine News(10 mins):
(Date:9/9/2017)... 9, 2017  Eli Lilly and Company (NYSE: ... endpoint data for lasmiditan, an investigational, oral, first-in-class molecule ... significant improvements compared to placebo in the Phase 3 ... the 18th Congress of the International Headache Society (IHC) ... data presented today demonstrate lasmiditan,s potential to reduce pain ...
(Date:9/7/2017)... Caris Life Sciences, a leading innovator ... of precision medicine, today announced results from two ... molecular profiling approach in guiding therapeutic strategies in ... (CGP+) with Caris Molecular Intelligence ® to ... level, leading to more therapeutic options and improved ...
(Date:9/7/2017)... , Sept. 7, 2017   BioLife Solutions , Inc. ... marketer of proprietary clinical grade cell and tissue hypothermic ... that Mike Rice , President and CEO, will be ... Rodman & Renshaw 19 th Annual Global ... time (12:25 p.m. Pacific time). The conference is being held ...
Breaking Medicine Technology: